| 產品名稱 | Kasumi-6 |
|---|---|
| 商品貨號 | B209465 |
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | myeloblast |
| Product Format | frozen |
| Morphology | myeloid leukemia |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute myeloid leukemia, subtype M2 |
| Age | 64 years adult |
| Gender | male |
| Ethnicity | Japanese |
| Applications | The Kasumi-6 cell line can serve as a model to study the cellular and molecular biology of the non-t(8;21) M2 type of myeloid leukemia and can elucidate the role of mutated C/EBPalpha in leukemogenesis.
|
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | 45, XY,-9,add(12)(p11),add(13)(p11)
Ref  Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245 |
| Derivation | The cell line was established from the blast cells of a myeloperoxidase-negative patient with relapsed acute myeloid leukemia (AML), FAB M2. The patient had received prior chemotherapy. |
| Clinical Data | 64 years adult
Japanese
male
|
| Antigen Expression | CD33+, CD13+, CD11b+, HLA-DR+, CD3-, CD14-, CD19-, CD41-, CD34 |
| Genes Expressed | Myeloperoxidase, negative C/EBP-alpha, hemizygous mutation protein positive
|
| Comments | Both the original leukemic cells and the Kasumi-6 cell line harbor a hemizygous point mutation in the gene encoding the CCAAT/enhancer binding protein alpha (C/EBPalpha), a critical myeloid transcriptional factor. The cells express C/EBPalpha protein but lack C/EBPalpha binding activity. 12-O-tetradecanoylphorbol-13-acetate (TPA) induces Kasumi- 6 cells to differentiate into adherent, monocytoid appearing cells. Differentiation Inducers: TPA |
| Complete Growth Medium | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 2 ng/ml human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) and 20% fetal bovine serum
|
| Subculturing | Cultures can be established by centrifugation with subsequent resuspension at 2 x 105 viable cells/mL.
Maintain cell density between 2 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 10% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 8,12 D16S539: 9,10 D5S818: 11 D7S820: 9,11 THO1: 6,9 TPOX: 8,9 vWA: 17 |
| Population Doubling Time | 55 hrs |
| Name of Depositor | H Asou |
| Year of Origin | January 1999 |
| References | Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245 Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
